Advertisement

Somatomedin Inhibitors

  • L. S. Phillips
  • S. Goldstein
  • J. D. Klein

Abstract

Direct measurement of growth hormone (GH) in problems of disordered growth has revealed conditions in which growth is poor despite the presence of GH levels which are normal to elevated (1). Studies of the potential involvement of the insulin-like growth factors/somatomedins (IGFs) in these GH-resistant states have indicated (a) that there is regulation of IGF generation by factors other than GH, and (b) that there is regulation of IGF action by other circulating factors, the IGF inhibitors. In malnutrition, diabetes, glucocorticoid excess, and renal failure, GH-resistant growth failure is associated with low circulating levels of IGF activity as measured by cartilage bioassay (Table 1).

Keywords

Sulfate Uptake Glucocorticoid Excess Size Exclusion HPLC Somatomedin Activity Hepatic Release 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Phillips, L.S. and Unterman, T.G. Somatomedin activity in disorders of nutrition and metabolism. Clinics Endocrinol Metab 13:145–188, 1984CrossRefGoogle Scholar
  2. 2.
    Phillips, L.S. and Young, H.S. Nutrition and somatomedin. I. Effect of fasting and refeeding on serum somatomedin activity and cartilage growth activity in rats. Endocrinology 99:304–314-438–446, 1976PubMedCrossRefGoogle Scholar
  3. 3.
    Phillips, L.S. and Young, H.S. Nutrition and somatomedin. II. Serum somatomedin activity and cartilage growth activity in streptozotoc in-diabetic rats. Diabetes 25:516–527, 1976PubMedCrossRefGoogle Scholar
  4. 4.
    Unterman, T.G. and Phillips, L.S. Glucocorticoid effects on somatomedins and somatomedin inhibitors. J Clin Endocrinol Metab 61:618–626, 1985PubMedCrossRefGoogle Scholar
  5. 5.
    Phillips, L.S., Fusco, A.C., Unterman, T.G. and del Greco, F. Somatomedin inhibitor in uremia. J Clin Endocrinol and Metab 59:764–772, 1984CrossRefGoogle Scholar
  6. 6.
    Goldstein, S., Stivaletta, L.A. and Phillips, L.S. Separation of somatomedins and somatomedin inhibitors by size exclusion high-performance liquid chromatography. J Chromatography 339:388–393, 1985CrossRefGoogle Scholar
  7. 7.
    Phillips, L.S., Belosky, D.C., Young, H.S. and Reichard, L.A. Nutrition and somatomedin. VI. Somatomedin activity and somatomedin inhibitory activity in serum from normal and diabetic rats. Endocrinology 104:1519–1524, 1979PubMedCrossRefGoogle Scholar
  8. 8.
    Phillips, L.S. “Somatomedin Inhibitors” (Proceedings of the International Workshop on Advances in Research on Human Growth, Airlie, VA. (In press, 1989)Google Scholar
  9. 9.
    Van den Brande, J.L. and Du Caju, M.V.L. Plasma somatomedin activity in children with growth disturbances. In: Advances in Human Growth Hormone Research, edited by Raiti, S. Washington: DHEW, 1974, p. 98–126.Google Scholar
  10. 10.
    Phillips, L.S., Belosky, D.C. and Reichard, L.A. Nutrition and somatomedin. V. Action and measurement of somatomedin inhibitor(s) in serum from diabetic rats. Endocrinology 104:1513–1518, 1979PubMedCrossRefGoogle Scholar
  11. 11.
    Vassilopoulou-Sellin, R., Foster, P.L., Oyedeji, C.O. and Sarnaan, N.A. Cartilage sulfation inhibitor from rat liver partial characterization of properties and biologic action. Metabolism 37:38–45, 1988PubMedCrossRefGoogle Scholar
  12. 12.
    Goldstein, S. and Phillips, L.S. Nutrition and Somatomedin XVIII. Nutritionally-regulated release of somatomedins and somatomedin inhibitors from perfused livers in rats. Metabolism (in press, 1989)Google Scholar
  13. 13.
    Phillips, L.S. and Scholz, T.D. Nutrition and somatomedin. IX. Blunting of insulin-like activity by inhibitor in diabetic rat serum. Diabetes 31:97–104, 1982CrossRefGoogle Scholar
  14. 14.
    Phillips, L.S., Vassilopoulou-Sellin, R. and Reichard, L.A. Nutrition and somatomedin. VIII. The “somatomedin inhibitor” in diabetic rat serum is a general growth cartilage inhibitor. Diabetes 28:919–924, 1979PubMedCrossRefGoogle Scholar
  15. 15.
    Sadler, T.W., Phillips, L.S. and Goldstein, S. Inhibition of mouse embryonic growth and development by a somatomedin inhibitor(s). Diabetes 35:861–865, 1986PubMedCrossRefGoogle Scholar
  16. 16.
    Phillips, L.S., Goldstein, S. and Gavin, III, J.R. Nutrition and somatomedin XVI. Somatomedins and somatomedin inhibitors in fasted and refed rats. Metabolism 37:209–216, 1988PubMedCrossRefGoogle Scholar
  17. 17.
    Hofert, J.F., Goldstein, S. and Phillips, L.S. Glucocorticoids are required for elevation of somatomedin inhibitors in diabetic rats. Metabolism (in press, 1989)Google Scholar
  18. 18.
    Phillips, L.S. and Kopple, J.D. Circulating somatomedin activity and sulfate levels in adults with normal and impaired kidney function. Metabolism 30:1091–1095, 1981PubMedCrossRefGoogle Scholar
  19. 19.
    Vassilopoulou-Sellin R., Phillips, L.S. and Reichard, L.A. Nutrition and somatomedin VII. Regulation of somatomedin activity by the perfused rat liver. Endocrinology 101:260–267, 1980CrossRefGoogle Scholar
  20. 20.
    Binoux, M., Lassarre, C. and Hardouin, N. Somatomedin production by rat liver in organ culture. I. Studies on the release of insulin-like growth factor and its carrier protein measured by radioligand assays. Effects of growth hormone, insulin and Cortisol. Acta Endocrinol 99:422–430, 1982PubMedGoogle Scholar
  21. 21.
    Binoux, M., Lassarre, C. and Seurin, A. Somatomedin production by rat liver in organ culture. II. Studies of cartilage sulphation inhibitors released by the liver and their separation from somatomedins. Acta Endocrinol 93:83–90, 1980PubMedGoogle Scholar
  22. 22.
    Binoux, M., Hossenlopp, P., Lassarre, C. and Seurin, D. Somatomedin production by rat liver in organ culture. III. Validity of the technique. Influence of the released material on cartilage sulphation. Effects of growth hormone and insulin. Acta Endocrinol 93:73–82, 1980PubMedGoogle Scholar
  23. 23.
    Phillips, L.S., Fusco, A.C. and Unterman, T.G. Nutrition and somatomedin. XIV. Altered levels of somatomedins and somatomedin inhibitors in rats with streptozotoc in-induced diabetes. Metabolism 34:765–770, 1985PubMedCrossRefGoogle Scholar
  24. 24.
    Gagliardi, A.R.T., Goldstein, S. and Phillips, L.S. Somatomedin inhibitor in diabetic rats: relation to ketogenesis and gluconeogenesis. Clin Res 36:23A, 1988 (Abstract)Google Scholar
  25. 25.
    Kelly, R.A., O’Hara, D.S., Mitch, W.E. and Smith, T.W. Identification of NaK-ATPase inhibitors in human plasma as nonesterified fatty acids and lysophospholipids. J Biol Cher. 261:11704–11711, 1986Google Scholar
  26. 26.
    Salmon, W.D., Jr. Interaction of somatomedin and a peptide inhibitor in serum of hypophysectomized and starved, pituitary-intact rats. Adv Metab Disord 8:183–199, 1975PubMedGoogle Scholar
  27. 27.
    Salmon, Jr., W.D., Holliday, L.A. and Burkhalter, V.J. Partial characterization of somatomedin inhibitor in starved rat serum. Endocrinology 112:360–370, 1983PubMedCrossRefGoogle Scholar
  28. 28.
    Brewer, M.T., Stetler, G.L., Squires, C.H., Thompson, R.C., Busby, W.H. and Clemmons, D.R. Cloning, characterization, and expression of a human insulin-like growth factor binding protein. Biochem Biophy Res Commun 152:1289–1297, 1988CrossRefGoogle Scholar
  29. 29.
    Brinkman, A., Groffen, C., Kortleve, D.J., van Kessel, A.G. and Drop, S.L.S. Isolation and characterization of a cDNA encoding the low olecular weight insulin-like growth facending protein (IBP-1). EMBO 7:2417–2423, 1988Google Scholar
  30. 30.
    Lee, Y-L., Hintz, R.L., James, P.M., Lee, P.D.K., Shively, J.E. and Powell, D.R. Insulin-like growth factor (IGF) binding protein complementary deoxyribonucleic acid from human HEP G2 hepatoma cells: predicted protein sequence suggests an IGF binding domain different from those of the IGF-1 and IGF-11 receptors. Molec Endocrinol 2:404–411, 1988CrossRefGoogle Scholar
  31. 31.
    Wood, W.I., Cachianes, G., Menzel, W.J., Winslow, G.A., Spencer, S.A., Hellmiss, R., Martin, J.L., Baxter, R.C. Cloning and expression of the growth hormone-dependent insulin-like growth factor-binding protein. Molec Endocrinol 2:1176–1185, 1988CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • L. S. Phillips
    • 1
  • S. Goldstein
    • 1
  • J. D. Klein
    • 1
  1. 1.Department of MedicineEmory University School of MedicineAtlantaUSA

Personalised recommendations